Tirzepatide is the same molecule in both pens. Lilly just sells it under two different brand names in the US, and the split decides which price lane you land in. That detail alone has shocked more pharmacy counters than I can count.

Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management in adults with obesity, and since 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. Same drug. Two labels. Two very different coverage stories.

Most patients get surprised by that split on the first pharmacy call — the long pause before "ma'am, that's not covered for that indication" is the soundtrack to month one. Rule of thumb for April 2026: if you have type 2 diabetes, your fight is with your PBM over Mounjaro. If you're there for weight, your fight is with your PBM over Zepbound — and if that fails, with yourself over whether the Lilly Self Pay vial lane is worth the tradeoff.

Mounjaro vs Zepbound: the US brand split in one table

Item	Mounjaro	Zepbound
Molecule	tirzepatide	tirzepatide
FDA indication	type 2 diabetes	obesity (BMI ≥30, or ≥27 with comorbidity); moderate-to-severe OSA in adults with obesity
Approval year	2022	2023 (OSA expansion 2024)
Typical commercial coverage	often covered with step therapy	frequently excluded from employer formularies
Medicare Part D	covered for T2D	not covered for obesity indication
Lilly Self Pay vials	no	yes, for 2.5 mg and 5 mg single-dose vials
List price (April 2026)	roughly $1,070 per month	roughly $1,060 per month for pens

The list prices sit close. The out-of-pocket reality doesn't. The path from list price to what your card gets charged runs through three separate doors: commercial PBM, Medicare, or cash through LillyDirect.

The SURMOUNT-5 head-to-head is the clinical reason people pay attention

Tirzepatide vs semaglutide, 72 weeks, published in NEJM in 2025 (Aronne LJ et al., SURMOUNT-5).

Endpoint at 72 weeks	Tirzepatide (max tolerated)	Semaglutide (max tolerated)
Mean body weight change	-20.2%	-13.7%
Share losing ≥15%	about 65%	about 40%
Share losing ≥25%	about 32%	about 16%

That -20.2% vs -13.7% gap — 6.5 percentage points — is the single number driving most switches from Wegovy to Zepbound in the US right now. On a 220 lb (100 kg) starting weight, that's roughly 14 lb of extra loss over 72 weeks. Not a rounding error. That's a jean size.

It's also why employer plans that still exclude obesity drugs are getting appeal letters naming SURMOUNT-5 by title. In 2026, clinicians writing PA appeals usually lead with that study.

Commercial insurance: the only lane where it gets cheap

If your employer's plan covers Zepbound, monthly out-of-pocket usually lands in the $25 to $75 range with the Zepbound Savings Card applied, depending on plan design and whether you've met your deductible.

That's the clean path. The messy path is more common.

Plans routinely require:

A documented BMI that meets the label (≥30, or ≥27 with a named comorbidity)
Prior failure of one or more older agents — phentermine, orlistat, sometimes Saxenda
A documented lifestyle-modification program, often 3 to 6 months of logged weight and counseling
Continued-coverage reauthorization at 3 or 6 months, gated on a minimum weight loss, often ≥5%

Miss one of those and the plan denies. Appeals win a fair share of the time, but "eventually" means 4 to 10 weeks of paperwork while your first pen sits on a pharmacy shelf with a $1,060 price tag and your inbox fills with PA-pending emails you can't do anything about.

Mounjaro for T2D has a different texture. It's more often on formulary, but step therapy is common — the plan wants you to fail metformin, and sometimes a sulfonylurea or a DPP-4, before paying for tirzepatide. For patients with a clear A1c picture plus cardiovascular or renal risk, step therapy clears faster.

If your PA gets denied, don't pay list price the next day. Ask your prescriber to file a formal appeal with the chart notes, BMI, comorbidity, and SURMOUNT-5 reference. Second-level appeals win more often than most patients expect.

Medicare and Medicaid: the quiet gap

This is the part US pricing articles usually hand-wave past.

Medicare Part D is statutorily prohibited from covering drugs "when used for weight loss." That's why Wegovy and Zepbound aren't covered by Medicare for the obesity indication in 2026. What shifted in 2024 was narrow. When Wegovy picked up the expanded label for reducing cardiovascular events in adults with established CV disease and overweight or obesity, Part D plans could cover semaglutide for that on-label CV indication — not for weight loss itself. Similar logic applies to Zepbound's OSA indication: if your clinician prescribes it for moderate-to-severe OSA, some plans cover it on that label even while excluding it for obesity alone.

That distinction matters at the pharmacy counter. "Zepbound for OSA" and "Zepbound for weight" can be the same pen, same dose, same patient — but one gets covered and the other gets rejected.

Medicaid is a state-by-state patchwork. Some states cover Wegovy and Zepbound for obesity with prior authorization; others exclude anti-obesity drugs entirely. If you're on Medicaid, your state's preferred drug list is the only document that answers the question.

Lilly Self Pay and LillyDirect: the cash lane for Zepbound

Lilly announced the Self Pay program in 2024 and expanded the vial offering through 2025. For April 2026, the publicly stated pricing sits in this range:

Zepbound lane (cash via LillyDirect / Lilly Self Pay)	Monthly price range
2.5 mg single-dose vial	about $349
5 mg single-dose vial	about $499
7.5 mg vial (where offered)	typically higher, in the $599 range
10 mg vial (where offered)	typically higher, in the $699 range
Pen, regardless of strength, retail	roughly $1,060 without coverage

The vial is where the math changes. Same tirzepatide as the pen, drawn up with a syringe instead of clicked out of a device. Self-administering from vials saves hundreds a month versus the pen. The tradeoff: dose titration is manual, and you have to be comfortable drawing the correct units.

A few things the vial program is not:

Not Mounjaro. Self Pay vials are a Zepbound program. Patients with type 2 diabetes whose plan denies Mounjaro can't sidestep to the vial for diabetes coverage.
Not automatic refill. Lilly requires the prescription to be written for the vial specifically, and LillyDirect fulfills through its own pharmacy partners.
Not a forever price. Lilly has moved these figures before and has room to move them again. Anchor your budget on the April 2026 posted price and re-check quarterly.

What "list price" actually means in the US

US drug pricing runs on three parallel numbers that hardly ever match.

Number	What it is	Who pays it
List price (WAC)	Wholesale acquisition cost posted by Lilly	almost nobody directly
Net price	What Lilly collects after PBM rebates	not public, estimated 40 to 60% of list
Cash / self-pay	What you pay without insurance	closer to net than to WAC

When an article says "Zepbound costs $1,060 a month," that's WAC. Sticker on the car nobody pays. Your real number is whatever falls out of the intersection of your plan's formulary, your deductible, your coinsurance, and the manufacturer coupon.

The Zepbound Savings Card caps eligible commercial patients at a defined monthly amount on covered fills, and a higher ceiling on uncovered fills — both with annual and per-fill savings caps. Coupon eligibility excludes Medicare, Medicaid, TRICARE, and VA patients. That last rule traps retirees who assume they can stack the coupon onto Part D. They can't.

Realistic monthly out-of-pocket, four common scenarios

Scenario	Typical monthly cost, April 2026
Commercial plan covers Zepbound, savings card applied	about $25 to $75
Commercial plan denies Zepbound, Lilly Self Pay 5 mg vial	about $499
Medicare patient with OSA indication, Part D covers Zepbound	Part D copay, often $40 to $100 at Tier 3
Medicare patient seeking Zepbound for weight only	not covered; cash path only

Add prescriber visit costs. A follow-up with an obesity-medicine specialist runs $150 to $350 without insurance, or a $25 to $60 copay with it. Telehealth obesity clinics like Ro, Sesame, and Weight Watchers Clinic sit in the $99 to $199 per-visit range, though membership bundles vary.

Annualized, a Lilly Self Pay 5 mg vial user lands near $6,000 in drug spend alone. A commercial-covered user with the card might come in under $900 for the year. Same patient. Same pen. Order of magnitude apart.

PBM step therapy and formulary tiers in plain language

CVS Caremark, Express Scripts, and OptumRx together cover most commercially insured Americans. Each one publishes a preferred drug list that changes at least annually, and the 2026 versions did not treat Zepbound and Wegovy identically.

Some CVS Caremark plans moved to "prefer one GLP-1" policies, where the plan covers either Wegovy or Zepbound, not both, and requires documented failure or intolerance of the preferred one before switching.
Express Scripts kept Zepbound on formulary for many employer clients but tightened PA language, specifically the comorbidity documentation for BMI 27 to 29.9 patients.
OptumRx varies by sponsor, with several large employers using OptumRx moving to exclude anti-obesity drugs entirely starting January 2026.

Practical consequence: your neighbor on the same drug might have a $30 copay while you get a denial. The difference isn't the drug. It's the employer's contract with the PBM.

When you call your pharmacy benefit, ask for three things: the current PA criteria for Zepbound, the tier placement, and whether the plan uses a "prefer one GLP-1" rule. Those three answers tell you what your year looks like.

Compounded tirzepatide: the lane that narrowed

During the 2023 to 2024 tirzepatide shortage, compounding pharmacies — both 503A (patient-specific) and 503B (outsourcing facilities) — filled prescriptions that FDA-approved product could not. The FDA declared the tirzepatide shortage resolved on December 19, 2024, which removed the primary legal basis for mass-market compounding of tirzepatide.

Where that leaves April 2026:

503B outsourcing facilities that were producing bulk compounded tirzepatide during the shortage no longer have a general shortage-based allowance.
503A pharmacies can still compound for an individual patient-specific prescription in defined clinical scenarios — for example, a documented allergy to an inactive ingredient in the FDA-approved product. Those scenarios are narrow.
Several telehealth platforms that were offering compounded tirzepatide for weight loss wound down or pivoted during 2025. A few continue to operate, but the legal exposure has changed materially.

For most patients in April 2026, compounded tirzepatide is no longer a meaningful cheaper alternative to Zepbound. If a telehealth site is still selling it for $199 a month, ask which 503A pharmacy is dispensing, on what clinical basis, and whether the prescriber has given you documentation that would survive a state board inquiry.

Side effects cost money too

The sticker price hides a secondary line item nobody writes into the budget: the first 8 to 12 weeks.

Across SURMOUNT-1 and the tirzepatide obesity program, gastrointestinal adverse events were the most common. Nausea hit roughly 24 to 33% of participants across doses; diarrhea about 19%; constipation around 17%; vomiting 10 to 12%. Most events were mild to moderate and clustered in the titration period. About 4 to 7% of participants discontinued for adverse events.

In the real world, that shows up as an extra urgent-care visit or two during months one and two — dehydration, an IV bag, an anti-emetic prescription. Call it $150 to $400 out of pocket if you hit that path. Put it on the first-quarter line in your budget. A lot of patients quit inside that window and end up paying for four weeks of drug with almost no durable weight change.

The patients who make it past week eight are the ones who front-load support in month one. Protein targets, electrolytes, a prescriber who picks up the phone when nausea spikes. Cheapest line item you'll ever add to this drug.

What to confirm before you fill the first pen

Five things, in order. If any of them are unresolved, don't fill yet.

Which brand is on the prescription and for which indication. Zepbound for obesity or OSA; Mounjaro for T2D. Pharmacies flag mismatches.
Your plan's PA status for that specific brand and indication. Not "GLP-1 coverage" in the abstract — the named drug, named indication.
The copay or cash price the pharmacy will actually run. Ask them to key it in before you commit, not after.
Whether the Zepbound Savings Card (for commercial) or Lilly Self Pay vial (for cash) is set up in the patient profile.
The refill cadence your plan requires. Some plans force 90-day fills after the first month, which changes when your next out-of-pocket hits.

That 10-minute pharmacy call saves a lot of patients from an $1,060 surprise on pickup day.

Questions to bring to your doctor

Short list, sharp list. Bring the printout.

Based on my BMI, comorbidities, and prior trials, am I better positioned clinically for Zepbound or, if I have T2D, for Mounjaro?
What is the realistic maintenance dose you are aiming at — 10 mg, 12.5 mg, or 15 mg once weekly — and why?
If I hit a plateau at month three or four, what is our plan: hold the dose, titrate up, or add something?
If my employer plan denies the PA, are you willing to file a first-level appeal citing SURMOUNT-5 and my specific comorbidity documentation?
What does tapering off look like if I need to stop, and how do we plan for the SURMOUNT-4-style weight regain risk after discontinuation?
How often do we recheck labs — A1c, lipids, kidney function — while I am on therapy?

A prescriber who answers "we'll figure it out as we go" on all six may not be the right prescriber for a drug that costs what this one costs.

A realistic read on the US market right now

Four bullets, as of April 2026.

Tirzepatide is the strongest GLP-1/GIP weight-loss option on the US market by head-to-head data. SURMOUNT-5's -20.2% vs -13.7% at 72 weeks is real, published in NEJM in 2025, and reshaping prescriber defaults.
Access is the bottleneck, not supply. The 2023 to 2024 shortage is resolved. What is not resolved is employer-plan exclusion of obesity drugs, Medicare's obesity carve-out, and the PBM formulary game.
Lilly Self Pay vials are the most important cash lane the US has ever had for a branded GLP-1 for obesity. At roughly $349 for 2.5 mg and $499 for 5 mg, a substantial share of previously priced-out patients have a viable path — assuming they are comfortable with vial-and-syringe administration.
Plan for a year, not a month. SURMOUNT-4 showed meaningful weight regain in the year after stopping tirzepatide. Budgeting for 12 months of therapy is a better frame than "let me try one pen and see." If 12 months of Self Pay vials at around $499 is not doable, be honest about it before month one, not after.

A useful mental model for US patients in 2026: there's no single "Zepbound price." There are three — commercial with coupon, Lilly Self Pay vial, and uncovered list — and your year is defined by which lane you can hold. Nail the lane first. The clinical questions get easier once the money question stops being a surprise every 28 days. That dread you feel when you see the pharmacy on caller ID? It quiets down once the lane is settled.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All GLP-1 medications discussed are prescription drugs — do not start, stop, or change any medication without consulting your doctor. Individual results vary. For the most current prescribing information, refer to the FDA-approved labeling for each drug.